Dimerix Limited Is An Australia Based Clinical Stage Biopharmaceutical Company Listed On The Australian Securities Exchange Under The Code Dxbfounded In 2004Dimerix Focuses On Developing And Commercializing Pharmaceutical Productsparticularly For Inflammatory Diseases Affecting The Kidneys And Respiratory Systemthe Company Operates Through Its Wholly Owned Subsidiarydimerix Biosciences Pty Ltdand Is Led By Drnina Webster As Ceo And Mrmark Diamond As Non Executive Chairman Dimerix Employs Its Proprietary Receptor Hit Technology To Create Novel Treatmentswith Dmx 200 Being One Of Its Key Drug Candidatesthe Company Adopts A Diversified Investment Strategyexploring Both New Chemical Entities And Repurposed Drugsin 2024Dimerix Reported Total Revenue Of $8 568 000Primarily From Scientific Research Servicesthe Company Emphasizes Environmentalsocialand Governanceesgconsiderations In Its Operations And Is Committed To Addressing Unmet Medical Needs In The Healthcare Sector
